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Searching for Cures 
for Emerging Infectious Diseases 
MESSAGE FROM THE DEA 
E V O L U T I O N A N D C H A N G E . The exceptional reputation of Boston University School 
of Medicine (BUSM) over the past century and a half has heen hased on the School's ahility to antici-
pate, emhrace, and react to these conditions. As we hegin the 21^* century and face new challenges on 
the campus and in the curriculum, we wi l l continue to adjust to provide innovative leadership in 
medical education. 
The School's evolution is evident on hoth physical and academic levels. From new construction 
projects to the plans for future expansion featured in the Campus Growth section (see page 14), the 
campus is continually expanding and improving. Academically, a new mentoring program aimed at 
helping our students get the most from their Medical School experience is ensuring that faculty 
encourage professional, ethical, and humanitarian values in our graduates (see page 10). Another 
exciting evolution is the opening of the Center for Biomedical Imaging, which houses a new magnetic 
resonance imaging scanner dedicated solely to research on the BU campus (see page 16). 
BUSM's evolution is continuing on a national level. In the feature "Bringing Research to a New 
Level" (see page 2), we proudly descrihe the Medical Center's selection to receive the $128 million fed-
eral award to huild a hiosafety level 4 lahoratory. Together with Boston Medical Center and the National 
Institute of Allergy and Infectious Diseases, BUSM researchers wi l l utilize the lahoratory to manage and 
direct research into emerging infectious diseases and agents of hioterrorism, such as anthrax, Ehola 
virus, plague, and smallpox. The lah is expected to generate $1.7 hillion in research during the next 20 
years, and the results from its research should henefit society as a whole. 
Perhaps the most prominent change that wi l l take place on campus in the near future wi l l he the 
naming of a new Medical School dean. The difficult process of selecting a new leader has hegun, and a 
national search is under way for candidates whose goals and personal characteristics fit with our insti-
tution. Already a long list has heen narrowed to approximately a dozen candidates, and interviews are 
ongoing. A handful of those interviewed wi l l meet with former BUSM Dean and current President ad 
interim Aram Chohanian this summer, and, i f the process continues on schedule, the School wi l l he 
welcoming hoth a new class and a new dean this fall. 
On a sad note, the School and the entire medical community lost a true friend this winter with 
the passing of Norman Levinsky. Having spent more than 40 years at BUSM as chairman of the 
Department of Medicine and chief of Renal Section in the Department of Medicine, Dr. Levinsky was 
a vital part of the foundation that keeps institutions such as ours strong. One of the longest-serving 
chairs of an academic medical department in the nation, he was a talented doctor, gifted investigator, 
good friend, and wise mentor. He touched the lives of so many colleagues, students, and patients and 
wi l l he sorely missed. 
In this time of transition, Thomas Moore, assistant provost for Clinical Research, professor of medi-
cine at BUSM, and director of the BUMC Office of Clinical Research, takes on the role of acting 
provost. Tom's skills as an outstanding clinician, academician, and administrator make him an excellent 
choice for this leadership position. 
Sincerely, 
John McCahan, M D 
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Bringing Research to a 
JN ew Leve 
BU Medical Center will soon build one of the most sophisticated laboratories 
in the world for studying emerging and re-emerging infectious diseases. 
Life expectancy for American citizens is at an all-time high, and medical 
research has played a large role in this achievement. Through decades of studying 
infectious diseases, investigators have been able to develop diagnostic tests, vac-
cines, and treatments to protect the public's health. The development and dissem-
ination of the polio vaccine, for example, has dramatically reduced the incidence 
of this disease. 
However the threat posed to society is continuous, as diseases naturally 
emerge and evolve. Even with medical advances, infectious diseases—HIV/AIDS, 
diarrheal diseases, and malaria, for instance—are a leading cause of death world-
wide. Recognizing this fact, the National Institute of Allergy and Infectious 
Diseases (NIAID) , part of the National Institutes of Health ( N I H ) , has led the 
endeavor in our nation to combat infectious diseases for more than 50 years by 
supporting medical research. 
When the anthrax attacks began in October 2001, the nation became acutely 
aware of another potential threat from disease—its use as a weapon of bioterror-
ism. In response, the NIAID devised a plan to expand its biodefense research. The 
goal: to protect the population against dangerous infectious diseases, whether they 
occur naturally or are purposefully released in a bioterrorist attack. 
As part of this national program, the N I A I D awarded Boston University 
Medical Center (BUMC) $128 mill ion to build a National Biocontainment 
Laboratory (NBL). It is one of the largest awards ever given to a university, and 
the application process was competitive. With this award, BUMC wil l construct a 
223,000-square-foot lab to be called the National Emerging Infectious Diseases 
Laboratories (NEIDL). The lab's mission wi l l be to develop diagnostic tests, treat-
ments, and vaccines for some of the most deadly infectious diseases known to 
mankind. 
"There is a huge void in our ability to respond to infectious diseases," says 
Mark Klempner, M D , associate provost for research at Boston University School of 
Medicine (BUSM), principal investigator of the grant, and director of the NEIDL. 
"The CDC [Centers for Disease Control and Prevention] tracks epidemics and 
specializes in rapid identification of diseases. But what it doesn't do and what we 
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"There is a huge void in our ability to respond to infectious diseases," says Mark Klempner, 
MD. "We need to better define how these microorganisms cause the diseases that they do. 
We need diagnostics, therapeutics, and vaccines. That's the void we're trying to fill." 
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"The level of infectious material that will be in the facility— 
and it will be in a lock-down state—will be very, very small," 
says John Murphy, PhD. 
don't have is a national strategy to rap-
idly diagnose, treat, and prevent these 
diseases. We need to better define how 
these microorganisms cause the diseases 
that they do. We need diagnostics, thera-
peutics, and vaccines. That's the void 
we're trying to f i l l ." 
Initially, the fundamental mission 
of the lab wi l l be to investigate and bet-
ter understand infectious diseases with a 
priority on what the CDC labels cate-
gory A agents, those microorganisms 
recognized as the most serious threats to 
public health. Researchers need to 
understand the pathogenesis of these 
diseases so they can identify points of 
intervention, says Klempner, whose 
research career has focused on the stud-
ies of infectious diseases. For the past 13 
years, he has worked mainly on emerg-
ing infectious diseases, particularly 
Lyme disease. 
Klempner defines emerging infec-
tious diseases as those that have newly 
surfaced by virtue of being previously 
unrecognized, citing severe acute respi-
ratory syndrome (SARS) and hepatitis C 
as examples. Re-emerging infectious dis-
eases, he says, are those the medical 
community has known about, but for 
various reasons these diseases weren't 
high priorities for researchers. "Lor 
example, there was no research going on 
for smallpox because the disease was 
gone," says Klempner. "However, it has 
re-emerged by virtue of the possibility 
that it could be used as an agent of terror." 
Characteristics of category A agents 
as defined by the CDC include high 
morbidity and mortality, ease of trans-
mission, and ability to cause large out-
breaks, therefore requiring special 
public health preparedness. Anthrax, 
botulism, tularemia, and plague are sev-
eral examples. "Category A agents are 
the bad actors, and we don't know a lot 
about them. There is an enormous 
amount of work that needs to be done," 
says John Murphy, PhD, co-principal 
investigator on the NBL grant, associate 
director of the NLIDL, and associate 
director of BUSM's graduate program in 
molecular medicine. 
Klempner asked Murphy to work 
with him on the project and help guide 
the science behind it because of 
Murphy's background: Not only does he 
have more than 20 years of experience 
as a researcher, focusing on bacterial 
toxinology and, more specifically, diph-
theria, but he also previously worked in 
a biosafety level 4 (BSL-4) lab. The gov-
ernment requires labs to meet certain 
safety levels depending on the agents 
that wi l l be handled. BSL-4, the highest 
containment rating, is used for the most 
dangerous microorganisms, such as cat-
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egory A agents. Because researchers wil l 
be working wi th these organisms at the 
NEIDL, it wi l l house a BSL-4 lab. 
To ensure the safety of both the 
lab's employees and the surrounding 
community, stringent security measures 
wi l l be instituted. A secured perimeter 
that meets Department of Defense stan-
dards wi l l surround the building, to 
which there wi l l be only two entrances. 
Security systems wi l l be in place at both 
entrances so that only people who pos-
sess the appropriate authorized identifi-
cation can enter. Once inside the 
building, codes wil l be required to 
access certain areas. To get to the BSL-4 
containment area, researchers wil l have 
to pass a biometric or iris scan and 
know codes, and then additional 
authorized employees with keys wi l l be 
required for access. The building wi l l 
have safety systems for air, water, and 
sewage. Researchers wil l don safety suits 
to do their work. These examples just 
skim the surface of the measures being 
taken. (Lor more details, see sidebar 
"How Safe Is It?") 
The focus of the entire building 
wi l l be on safety for the researchers, 
employees, community, and environ-
ment. BUMC can turn to the history of 
operation of BSL-4 labs for reassurance. 
Five such labs already exist in North 
America (four in the United States, one 
in Canada), and during their more than 
77 years of combined operation, there 
has never been a community incident or 
environmental release of an agent. "The 
technology going into these buildings is 
state of the art," says Murphy. "And on 
top of that, the level of infectious mate-
rial that wi l l be in the facility—and it 
wi l l be in a lock-down state—will be 
very, very small." 
In fact, only 13 percent of the 
building's net space wi l l be devoted to 
BSL-4 work. Most research into infec-
tious diseases concentrates on using 
pieces of the organism—proteins, DNA, 
How Safe Is It? 
Inside a biosafety level 4 (BSL-4) lab 
reside some of the most potentially 
dangerous microorganisms known to 
mankind. To protect both the staff 
and the surrounding community, 
security and safety experts design 
and construct BSL-4 labs to meet 
the strictest government standards. 
Following are some of the features 
that will make Boston University 
Medical Center's National Emerging 
Infectious Diseases Laboratories 
(NEIDL) one of the safest and most 
secure facilities in the world. 
Perimeter fencing designed to meet 
state and Department of Defense 
standards will surround the NEIDL 
at a distance of 150 feet. Those 
entering the building will encounter 
a secured entry system that will 
include optical turnstiles, security 
guards, metal detectors, closed-
circuit television surveillance, intru-
sion alarms, and other devices. 
Personnel, who will undergo back-
ground checks before hiring, may 
enter only the areas for which they 
are specifically authorized. The fur-
ther into the building they go, the 
more clearance they'll need. Gaining 
access to the agents, which will be 
kept in locked liquid-nitrogen con-
tainers, will require two researchers, 
both of whom will have to pass bio-
metric or iris scans and know codes. 
Unlocking the microorganisms will 
require two keys. 
The building will be completely 
airtight—all the seams, joints, and 
doors will be sealed. The air that flows 
in and out of the building will be 
double filtered using high-efficiency 
particulate air (HEPA) filters. The 
ultra-fine fibers in HEPA filters can 
trap any airborne bacteria or virus 
and remove microscopic particles of 
0.3 microns and smaller from the air 
with almost 100 percent efficiency. 
(A typical bacterium measures 
1 micron in length.) 
Nothing will leave the lab without 
first undergoing decontamination. 
Other safety features include air-
locks, fumigation chambers, disinfec-
tant dunk tanks, and wastewater 
treatment systems. Redundancies, 
such as backup power sources, as 
well as buffer corridors and floors 
surrounding the lab areas, will pro-
vide extra layers of protection. 
Beyond the physical design of the 
building, researchers will take even 
further safety measures. Before enter-
ing the BSL-4 lab, they will be required 
to take off everything, including jew-
elry, and take a decontaminating 
shower. Next they'll put on special 
surgical scrubs and booties; their 
double-layered gloves will be taped 
at the wrists to seal the junction 
with the suit. Once sealed in their 
suits, researchers will enter the bio-
containment area through an airlock 
where they will plug into an air source. 
Before leaving they will take another 
disinfectant shower while still fully 
suited. Work surfaces will be regularly 
decontaminated, and solid and liquid 
waste will be decontaminated and 
meet or exceed the environmental 
standards of the neighboring com-
munity before it leaves the facility. 
and RNA molecules—that are not infec-
tious or dangerous, says Klempner. 
Researching, creating, and verifying vac-
cines—all of this work can be done in 
BSL-2 and BSL-3 labs, which wi l l 
occupy the majority of the research 
institute. "Only those pieces where there 
is a risk of infection to the workers and 
exposure to intact infectious material 
wi l l be done at BSL-4. That occupies 
generally a tiny piece of the overall 
research agenda," says Klempner. "It's a 
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very important piece. And certainly 
when you get to the point of doing chal-
lenge experiments where you're trying 
to see i f a vaccine is protective, that has 
to be done at BSL-4." 
Murphy adds that because of all the 
precautions that must be taken, like 
donning safety suits, the object is not to 
work at BSL-4 unless it's absolutely nec-
essary. " I suppose the analogy you could 
make is it's like playing Beethoven's 
Lifth through large inflexible rubber 
gloves. You can do it, but you really have 
to want to," he says. 
In addition to the BSL-4 lab, the 
facility wi l l contain 11 state-of-the-art 
core laboratories, making this facility 
one of the most sophisticated research 
labs in the world to do emerging and re-
emerging infectious disease research. 
"The origin of these labs came from us 
asking during the design phase 'what 
kind of facility and technologies wi l l be 
on the cutting edge ten years from 
now?'" says Klempner. 
Some of the more cutting-edge core 
labs wil l be in the area of imaging, from 
cellular and molecular imaging to whole 
animal imaging, says Klempner. Lor 
example, the Cell & Tissue Imaging Core 
will offer such high-tech equipment as a 
cryo-electron microscope, a microtome, 
a confocal microscope, and a deltavision 
system. Researchers wil l be able to exam-
ine tissue, cell, and other biological 
specimens for research and diagnostic 
purposes, as well as visualize molecules 
in living and fixed tissues, cells, and 
organisms in multiple dimensions. 
The imaging core wi l l also house 
two of the most powerful MRI scanners 
available for nonhuman research, a 9.4-
tesla unit and a 4.7-tesla unit. Researchers 
wi l l be able to conduct dynamic func-
tional M R I studies using spin-echo and 
gradient-echo imaging techniques, as 
well as cerebral blood flow (CBL) 
enhancing techniques. Additionally, they 
wi l l he able to perform perfusion stud-
ies using spin-labeling techniques for 
hoth clinical and functional studies. 
There wi l l also he a High 
Throughput Screening Core, notes 
Klempner, which wi l l he used for comhi-
More Than a BSL-4 Lab 
Along with the biosafety level 4 (BSL-4) lab, the National 
Emerging Infectious Diseases Laboratories will house 11 core 
laboratories offering the best high-tech equipment available. 
These core labs will support the following functions: 
A Biomolecule Production Core will support the expression 
and purification of proteins, toxins, toxin subunits, antigenic 
peptides, carbohydrates, and other biologies in sufficient 
quantities for preclinical in vitro and in vivo studies. 
A Specimen Processing & Microbiology Core will be used to 
identify the presence of infectious agents in tissue, cell cul-
ture, or environmental specimens. 
A Cell & Tissue Imaging Core will be used to examine tissue, 
cell, and other biological specimens for research and diagnos-
tic purposes, as well as to visualize molecules in living and 
fixed tissues, cells, and organisms in multiple dimensions. 
A General Clinical Research Center will be used to study pre-
vention and treatments for emerging infectious diseases. 
An Immunology Core will offer basic cell separation services 
using magnetic separation and fluorescent activated cell sort-
ing (FAGS). Researchers will also be able to monitor the cyto-
toxicity of infected cell populations and study changes in 
surface antigen expressions in cells that have been infected 
by pathogens. 
An Insectarium Core will offer containment levels 3 and 4 to 
support research on potential and known arthropod vectors 
associated with these infectious diseases. 
An Aerobiology Core will allow researchers to study how 
infectious agents are transmitted by the aerosol route. 
A High Throughput Screening Core will help researchers 
develop small molecule libraries of unprecedented complex-
ity that they can use to identify therapeutic leads. 
A Cenomics/Mlcroarray core will allow researchers to ana-
lyze global gene expression patterns and assess the regula-
tion of response genes following infection, immunization, or 
challenge. 
A Proteomics/Mass Spectrometry Core will contain state-of-
the-art liquid chromatographic (LC) separation technology 
and allow for mass spectrometry analysis, including mass 
spectrometry sequencing and post-translational modification 
of proteins. 
A Bioinformatics Core will support researchers in the develop-
ment of high-throughput gene inference methods that can be 
applied to biological samples. It will also support the develop-
ment of metabolomic, proteomic, and genomic fingerprinting. 
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natorial small molecule libraries. "There 
are now ways being researched, including 
here at BU, of taking a single molecule 
and then modifying little parts of it to 
create, say, 50 molecules that relate to 
that one core molecule. It's called combi-
natorial chemistry. These create large 
libraries of molecules. With this facility, 
you could take literally a million com-
pound library and screen it very rapidly 
for an activity. So let's say you wanted to 
interfere with the replication of a partic-
ular microorganism, like a spore. You 
could screen an entire combinatorial 
library in this facility," says Klempner. 
Because many infectious diseases are 
transmitted by insects, the facility wi l l 
house an Insectarium Core. It wi l l sup-
port research on arthropod vectors asso-
ciated wi th human disease, such as 
mosquitoes and ticks, and wi l l contain 
stereo zoom microscopes, as well as 
chill and downdraff tables. "Often there 
is an intermediate host in the transmis-
sion of diseases, and I believe there's a 
real opportunity to study the interface 
between the vector, the intermediate 
host, and the human," says Klempner. 
"So we're going to spend, I hope, a fair 
amount of time investigating the rela-
tionship of the vector and the inter-
mediate host. It may be possible to 
interrupt the whole transmission cycle 
by researching how we can make the 
intermediate host immune from that 
transmission." 
In addition to advancing research, 
the NEIDL wil l also act as a training 
facility, educating first responders and 
fire, police, and medical personnel about 
how to handle exposure to infectious 
agents. To do that, it wi l l include a BSL-4 
training simulator located outside of the 
containment area but identical to a BSL-4 
environment. Here responders and 
researchers wi l l learn how to work in 
such a lab as well as practice emergency 
responses to various situations. 
In the event of a national emer-
gency the facility would work with the 
government to help in meeting the cri-
sis. "Our mandate as an NBL in the 
event of a national emergency is to sup-
plement what is the existing plan for 
response," Klempner explains. "Lor 
example, i f the CDC were overwhelmed 
with checking specimens from a poten-
tial environmental release, as was the 
case with the anthrax letters, where they 
had thousands of specimens, I think this 
laboratory would suddenly change its 
priority to devote its attention for that 
period of time to be a supplementary 
lab to other government facilities. 
"In addition, we wi l l have one of the 
greatest collections of intellectual exper-
tise on emerging and re-emerging infec-
tious diseases and bioterror agents," says 
Klempner. "We wil l actually be right on 
that front line. So i f there's a question—a 
patient shows up with certain symptoms, 
for example, and there's a question of 
whether we should quarantine a popula-
tion, we wil l have the expertise right here, 
and we wi l l assist the government by pro-
viding immediate advice." 
Although the NLIDL's role in 
national security wi l l take center stage, 
Klempner believes research on a wide 
variety of emerging infectious diseases, 
including those not categorized as top 
priority by the NIAID, eventually wi l l be 
interwoven with its agenda. He also 
anticipates that a large number of 
spillover technologies from the advances 
made in this laboratory wi l l positively 
affect research of more common infec-
tious diseases, like the cold. "There is a 
relatively limited number of pathways 
that we can break down as host barriers. 
And by understanding them better, you 
can transmit those ideas into a better 
understanding of other infectious dis-
eases," says Klempner. "And it's a yet 
poorly defined set of rules that govern 
how the immune response works to 
these infectious diseases. By better 
understanding them we'll better be able 
to devise vaccines and immunotherapies. 
I really think there wi l l be big spin-offs 
and major public health benefits." 
Not only wi l l the nation and society 
as a whole benefit from this work, 
Klempner adds, but BUMC and the city 
of Boston stand to gain from the devel-
opment of this project. During the 
building phase, which is scheduled to 
begin sometime in 2005 and end in 
2007, more than 1,300 construction jobs 
wi l l be created. Klempner estimates 
another 660 jobs wi l l result from the 
lab's operations. Over the next 20 years, 
approximately $1.3 bil l ion w i l l go into 
the building and operation of the 
NLIDL, about $180 mil l ion for con-
struction, $10 to $20 mil l ion annually 
for operation, and $50 to $70 mil l ion 
annually from funded research. 
Klempner believes the laboratory 
wi l l attract more of the best and bright-
est researchers to BUMC. "This wi l l shift 
the epicenter for some kinds of research 
to BUMC," he says, "and wi l l help make 
it the best urban academic and treat-
ment center in the world." • 
Klempner anticipates that a large number of spillover 
technologies from the advances made in this laboratory 
will positively affect research of more common infectious 
diseases, like the cold. 
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with Mark Klempner and John Murphy 
Although numerous people 
played a role in winning the 
National Institute of Allergy and 
Infectious Diseases (NIAID) award to 
huild a National Biocontainment 
Lahoratory (NBL) at Boston University 
Medical Center (BUMC), two were 
leaders in making it happen. Mark 
Klempner, M D , associate provost for 
research at Boston University School of 
Medicine (BUSM), was principal inves-
tigator of the grant and is now director 
of what wi l l be named the National 
Emerging Infectious Diseases Labo-
ratories (NLIDL) . And John Murphy, 
PhD, associate director of BUSM's 
graduate program in molecular medi-
cine, was co-principal investigator of 
the grant and is now associate director 
of the NLIDL. 
Klempner's long-standing research 
on infectious diseases led h im to pursue 
the project. He asked Murphy to work 
wi th h im because of his background in 
bacterial toxinology research and expe-
rience wi th biosafety level 4 (BSL-4) 
work. A BSL-4 lab, designed to contain 
the most lethal microorganisms, wi l l 
play a major role in the NLIDL's opera-
tions, allowing researchers to realize 
their mission of studying emerging and 
re-emerging infectious diseases with 
the aim of developing countermeasures. 
Boston University Medicine talked 
to Klempner and Murphy about why 
such a facility is needed and why 
BUMC makes sense for its location. 
BU Medicine: What made the govern-
ment decide it needed the NBL? 
Murphy: Lollowing 9/11 and shortly 
after the anthrax incidents, the N I H 
(National Institutes of Health) put 
together a blue-ribbon panel. Its charge 
was to assess the capacity wi th in the 
United States to conduct research on 
emerging and re-emerging infectious 
diseases. And so essentially this blue-
ribbon panel found the infrastructure 
we have is lacking in groups of investi-
gators who are working on these 
organisms and lacking the kind of 
physical laboratory space that allows 
one to work wi th agents. 
Klempner: Then in August of 2002 the 
N I H held an informal meeting on its 
upcoming biodefense program in 
which it outlined that there would 
likely be three components. One com-
ponent would be Regional Centers of 
Excellence, which would be groups of 
scientists in various regions of the 
country collaborating to work on the 
major goals of category A agents [those 
most likely to be used for bioterrorism] 
and emerging infectious diseases. Some 
small facilities would support them. 
Mark Klempner, MD John Murphy, PhD 
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which came to be known as Regional 
Biocontainment Laboratories. And 
then there was the third component, 
which we chose to apply for, which was 
the two National Biocontainment Labs. 
[Another NBL w i l l be constructed at 
the University of Texas Medical Branch 
in Galveston.] 
BU Medicine: What made you think 
BUMC would be best positioned for this? 
Klempner: Lirst, this project needed a 
big superstructure to oversee it, and it 
needed a superstructure that had a place 
to put a building—a physical location. 
We were developing BioSquare, a bio-
medical research park. Second, it needed 
to be tied to the ability to become a 
national resource in the event of an 
emergency, a first responder adjunct. Our 
institution has a long history of being a 
first responder. We have the busiest level 
1 trauma care in the Boston area, and we 
work closely with the command center 
for the Boston Public Health commis-
sioner and the emergency management 
systems. Third, there needed to be a 
strong tie to a large cohort of collaborat-
ing scientists. We have that within our 
own institutions, as well as others within 
the New England region. 
Murphy: Mark recognized that the 
establishment of a national laboratory 
in the city of Boston with its surround-
ing expertise—not only the Harvard 
Regional Center of Excellence but also 
investigators at places like M I T and the 
BU Photonics Center—would really be a 
spectacular resource for the region and 
for the nation. 
BU Medicine: So even though some 
people ask why would you put such a 
facility in an urban area, you're saying 
the fact that we're in Boston is key to 
this facility's success? 
Murphy: Yes. Plus you need to be able 
to attract talent. This facility has the 
potential to be the premier infectious 
disease research facility in the world. 
That's a magnet. That's a magnet for 
people who are young, energetic, dedi-
cated to learning. And it's an enormous 
responsibility to those of us who have 
been given the charge to build this facil-
ity. And it's a responsibility we're taking 
very seriously. 
BU Medicine: What was the reaction of 
then Dean Aram Chobanian when you 
talked to him about the proposal? 
Klempner: 1 think he was skeptical at 
first but at the same time excited by 
what appeared to be a good match and 
an interesting opportunity that would 
catapult the Medical Center into a pre-
mier leadership role in the nation in the 
area of infectious diseases research. 
BU Medicine: On a more personal level, 
what are you most excited about in 
terms of where your research might go? 
Klempner: Everything! Lrom the 
specifics of my own research, I 'm very 
interested in the interface between the 
vector and the intermediate host. I've 
spent a lot of time on vector-born dis-
eases. I 'm hopeful that I wi l l continue to 
be able to develop a program to look at 
that interface. 
I also have a particular interest in 
technology that can be used in sensors 
to detect microorganisms for rapid 
diagnosis. Lor example, some of the 
most difficult questions we face every 
day result from when we find a white 
spot on a chest X-ray. Is that pneumo-
nia, an infectious disease, excess fluid, 
or a blockage because of a pulmonary 
embolism? To have a rapid sensing 
method to take a droplet of sputum and 
say that patient has pneumonia would 
be a huge step forward. 
But the overarching thing for me 
personally is this is a dream come true. 1 
come from a background of basic sci-
ence being translated into clinical sci-
ence. And when 1 sat down to devise 
and design the program that was going 
in the facility, the guiding principle to 
me was "what wi l l you need at each step 
of the development piece to get usable 
products that help the American pub-
lic?" You know, you don't get to do that 
often in your career. 
Murphy: This lab wi l l allow us to go 
into new areas, and wi th creativity, hard 
work, and some good luck we hopefully 
wi l l come up with new approaches to 
treat emerging and re-emerging infec-
tious diseases in a way that we haven't 
been able to do. And we wi l l be able to 
do this because we wi l l have the physical 
containment necessary to work under 
and the great safety that protects the 
investigators. 
Back when 1 worked in a level 4 lab, 
1 worked on genetically re-engineering 
diphtheria toxin. That work resulted in 
a whole new class of therapies, and the 
first drug was approved by the LDA 
four years ago. It's being marketed 
under the name Ontak and is used to 
treat cancer patients. Recent studies 
show the drug is working. In one study, 
7 of 22 patients had complete resolution. 
Complete—these patients would've 
died. And 9 had partial response. This 
is a drug that was developed under 
biosafety level 4 initially. 
That's why I do what 1 do. It's not to 
make money. It is to try and do good. • 
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A Novel System Helps 
Mentor Students 
The Academies of Advisors, a new mentoring program, aims to 
provide students with not only advice, but also role models. 
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鵡宜 edical school is
¥
tough-aCademically and personally.
Students face packed schedules,
demanding classes, and di飾cult career
decisions.
For years, faculty advisors have
PrOVided students with the chance to
talk to someone who knows the ropes
and can help them navlgate their way.
But unfortunately, nOt all students took
advantage of this system. “Some stu-
dents were gettmg WOnderful advising,
but we also had students who just
Weren’t gettmg the advice they needed;’
SayS Phyllis Carr, MD, aSSOCiate profes-
sor of medicine and associate dean for
Student Affairs. “In general, Students
Who were more assertive in gettmg their
needs met had a better experience.’’
Tb rectify this problem, Carr
devised a new mentonng System Called
the Academies of Advisors that began
With the dass of 2007. The mandatory
PrOgram enSureS that students meet
with their advisors several times a
SemeSter On both an academic and per-
SOnal basis. While improvmg the advis-
mg, the program also aims to promote
PrOfessional, ethical, and humanitarian
Values by exposmg Students to the
School’s best educators and role models.
“This is meant to even the playmg
field a bit for our students and give them
a lot of input regarding their medical
CareerS;’says carr. “There are all kinds
Of things you can do with a medical
< 」ohn Sco看aro says getting to
know his advisor, Phy冊s Car「,
MD, OutSide of class has made
her more approachabIe,
degree, and all kinds of avenues are
being opened up to these students while
th y are here. But they’re so busy with
their s udies, they sometimes don’t have
time to pursue them. They don’t have
t me to宜gure out who they should talk
to about things. Having one person who
knows the SchooI well, Who knows the
POSSibil ties in medicine, Who they meet
With on a regular basis, if only to say `I
think this is interestmg. How can I find
Out mOre?’-1t lVeS Students the ability
to maximize their education.’’
T  Aca emies of Advisors-
COmPOSed of six academies-facilitates
Smaller group activities within the med-
ic  school. Six deans from the O飾.ce
Of Student Affa. s, O鯖ce of Academic
A徹しirs, and the Admissions O縦ce serve
as the heads of each academy. In addi-
tion each academy also has a basic
SCien is , a SurgeOn, a Prlmary Care
Physician, and a specialist. All of these
faculty memb rs serve as core advisors,
With each currently handling about
five students. (After a11 four years are
induded, advisors wi11 mentor approxi-
mately 20 students each.)
Tb choose particIPatmg faculty,
Carr with the help of the Academies
Committ e and Ana Bediako, director
Of the program, COnducted an extensive
SearCh・ They asked students who they
thought w re the best teachers and advi-
SOrS, nd they asked faculty the same
questions. “We basically picked our best
teachers and mentors to be part of these
academies,” says carr.
In addition to these core advisors,
there also are at-large advisors who
include senior staff and junior faculty,
as well as potential future replacements
for the core advisory positions. This
s aff assists the core advisors and attends
many of the functions. “It’s sort of a
COnglomerate;’says carr. “It includes
PeOPl who we thought were really valu-
able but wouldn’t be around 12 months
a year to b  available to students and
Other faculty whose work demands do
not permit their full integration as core
academy mem ers.’’
When students enter their third
year and select a specialty, they will also
WOrk with field-SPeCi丘c advisors who
Will help m leam about their special-
ties. T se advisors will help students
With the application processes for
internships and residencies as well.
Ad itionally, Student volunteers within
the ame cademy will serve as peer
adviso s to students one year behind
them・ While the peer advising system
has been operational for some years,
having血is function w皿in the Academies
will increase the interclass connections
and further strengthen the structure. `A
Iot of thought and effort went into the
design of this program to make it
unlque tO BU;’says carr・
The actual program consists of
SeVeral elements. During the academic
y ar, Students meet twice a semester
with their advisors in one-On-One meet-
ings. (Students can request an appoint-
ment with their advisors any tlme they
may need help.) These meetings give
Students a chance to ask questions, and
advisors can offer assistance to anyone
Who m ght be struggling academically.
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Advisors also host two informal dinners 
per year for their advisees. To further 
increase faculty and student interac-
tions, social events are held throughout 
the year that include either all of the 
academies or groups of the academies. 
"We want to promote greater interaction 
outside of the classroom in the hopes it 
wil l lead to informal discussions and 
mentoring, acculturation to the profes-
sion, and exposure to some of our best 
role models," says Carr. "We want to 
help students acquire the professional-
ism we know they'll need." 
As part of her academy's planned 
events, Carr hosted a brunch at the 
beginning of the year. Carr's advisees 
attended, as well as the at-large advisors 
who work with her. "I t allowed students 
to meet each other, but also people from 
different disciplines," she says. 
Chi-Chi Adimora and John Scolaro, 
both of whom have Carr as an advisor, 
agree that the event was beneficial to 
students. "It was a great day, just getting 
to know the advisors outside of school," 
says Scolaro. "I t sounds kind of cliche, 
but I think it's important because it 
makes that person more approachable 
once you're in school. I wouldn't feel 
intimidated to go to Dr. Carr's office i f 
I needed something, because from the 
very beginning I was able to create a 
relationship that was at least somewhat 
comfortable for myself." 
Adimora feels the same. " I think it's 
good right from the beginning to get to 
know a professional who you can talk to 
and ask questions," she says. 
Sohini Shah, who came to the 
School of Medicine through the Boston 
Paul O'Bryan, PhD, and his advisee, 
Sohini Shah, discuss how her first year 
of medical school is progressing. 
University (BU) MMEDIC program 
(early acceptance into medical school 
for BU students), says her advisor, Paul 
O'Bryan, PhD, professor of physiology 
and biophysics and assistant dean for 
Student Affairs, took her group to 
lunch. "It was still summerish out so we 
were able to eat outside by the water. It 
was really nice. It was very informal 
chatting—a lot of questions about med 
school, obviously, because nobody knew 
what to expect. But then there was also 
just general talking and getting to know 
each other," she says. 
Shah's father owns a business and 
her mother works as a biotechnology 
researcher, making Shah the first in her 
family to go to medical school. Down 
the road, she foresees talking to her 
advisor about how to navigate medical 
school and for career advice. " I 'm sure 
I ' l l talk about taking the board exams 
and applying for residencies and choos-
ing elective rotations. That is what I'm 
going to need help with, because I don't 
know anybody who I can ask about that 
stuff," she says. 
Getting advice is a top priority for 
Adimora and Scolaro, too. Adimora, for 
example, says she needs help planning 
her summer. She is participating in 
the U.S. Army Health Professions 
12 B O S T O N U N I V E R S I T Y M E D I C I N E 
Scholarship Program, which pays for 
medical school in return for serving as 
an Army doctor for a certain length of 
time (dependent on the years of the 
scholarship). " I have to go to boot camp 
for six weeks this summer, but I want to 
do something with the rest of the four 
weeks I have left," says Adimora. " I don't 
know exactly what would be available, 
because most programs usually run six 
to ten weeks." 
Scolaro also wants to ask Carr for 
advice on how to spend some upcoming 
free time. He entered the medical school 
after attending the BU Master's in 
Medical Sciences program, during which 
he took several medical school courses. 
As a result, his course load next semester 
wi l l be a little lighter. " I 'm wondering i f 
I should be doing more clinical stuff, 
like shadowing a doctor or being 
involved in some clinical research. Or 
i f I should go back to the lab where I 
worked during grad school. Or should 
I use the time to get involved with a 
volunteer program outside of med 
school," says Scolaro. 
"Residency positions are all com-
petitive. You want to make the right 
moves at each step of the way," he adds. 
"So that's one thing I ' l l really be relying 
on Dr. Carr for, because you get differ-
ent opinions from different people. But 
she's someone who has written Dean's 
letters for many years and has dealt with 
people who are applying to residency 
programs and knows the workings of 
medical schools and hospitals. She'll be 
a pretty straight shooter at telling me 
what the best thing is for me to do." 
Although the program is still new 
and may encounter a few kinks as it 
continues to develop, Carr believes it's 
off to a good start. The students have 
been enthusiastic, she says, and actually 
have requested more events. Participating 
professors have responded equally well. 
"It's been really gratifying to have pro-
fessors who've been here for years come 
up to me and say 'this is wonderful,'" 
says Carr. " I t draws them into the expe-
rience of our students. And that's a very 
good thing, because you know some-
times we forget how hard medical 
school has become, how much informa-
tion and knowledge there is to acquire, 
and how stressful it is for students. It 
makes us all much more of a commu-
nity, being involved together in this." • 
Chi-Chi Adimora likes that she can talk 
to and gain knowledge of the profession 
from her advisor, Phyllis Carr, MD. 
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Campus Growth 
The Boston University Medical Center campus is continually 
expanding. Here are some of the works in progress. 
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Groundbreaking will commence 
this spring on the J. Joseph Moakley 
Medical Service Building at BMC. 
Once complete, the facility will con-
solidate cancer care for patients and 
allow the Medical Center to expand 
care. It is expected to he completed 
in the summer of 2006. 
In 2005, construction on the 
$128 million National Emerging 
Infectious Diseases Laboratories 
will hegin. The 223,000-square-
foot building will house some of 
the most sophisticated labs in the 
world for the study of infectious 
diseases. The project is expected 
to wrap up in 2007. 
An ahoveground 
parking garage is 
being built concur-
rently with the third 
BioSquare labora-
tory. It's expected 
to be completed in 
August 2005. 
Construction is under way on the third BioSquare 
laboratory building. Located at 670 Albany St., the 
176,000-square-foot facility should be completed 
in August 2005. 
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The recently established Center for Biomedical Imaging gives 
BU investigators access to a high-powered magnetic resonance 
imaging (MRI) scanner that's devoted to research. 
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that mappmg Of the human genome will
PrOVe tO be one ofthe most important
research-related developments in history,
a similar argument could be made for
the invention of magnetic resonance
imaging (MRI)・ This noninvasive diag-
nostic machine produces two- and three-
dimensional computerized images,
glVmg doctors and researchers the ability
to Iook inside a living body without the
use of radioIogy or surgical tooIs.
Boston University (BU) investigators
on both the medical school and Charles
River campuses have been empIoymg
MRI as part of their research for more
than a decade, but they,ve had to go o任i
Site and use other facilities, equlPment・
Not only did they often receive less-than-
desirable time sIots to conduct their
research, SOmetimes as late as 2 a.m., but
they also had little controI over the MRI
SCanner and their data.
With the openmg Of BU,s center
for Biomedical Imaglng’all of that
Changes. This new facility, 1ocated in
the Evans Biomedical Research Center
in BioSquare on the medical campus’
glVeS investlgatOrS aCCeSS tO the first
high-丘eld, Wide-bore MRI scanner
dedicated to research at BU・ Although
any mVeStlgatOr Can Pay tO uSe the
facility, BU researchers will have prefer-
ence and pay a lower fね
“We would like the center to be a
focal point for any research proJeCt On
CamPuS that invoIves MRI,,, says Dae-
Shik Kim, PhD, director of the center and
< Dae-Shik Kim, PhD, nationaIly recognized
for his wo「k in functional MRi, Came tO
BUSM to run the new Cente「 for
Biomedica=mag皿g,
Boston University SchooI of Medicine
(BUSM) associate professor of anatomy
and neurobioIogy. Kim, Who came to
BUSM丘om血e Universlty Of Mimesota,
SPeCializes in neuroimagmg and is known
nationally for his work in a technique
called functional MRI.
According to Kim, funded research
Wi11 t ke preference over nonfunded.
However, the center is settmg aSide
a ut 20 t  25 p rcent ofthe time sIots
for nonfunded pilot studies to be chosen
by a committee and based on merit. “We
ave to leave room for the people who
ar  not funded so they can get prelimi-
nary data and receive funding, SayS Kim.
T e center provides researchers
W th state-Ofthe-art equlPment, Startmg
With a 3-teSla MRI scanner丘om Philips.
A tesla is a unit of magnetic flux den-
Slty; the higher the tesla, the stronger the
magnet・ “Think of it this way-1 tesla is
lO・000 gauss, and the natural magnetic
field of th  earth is somewhere around
O.5 t  l gauss,’’explains Kim・ αThe mag-
net in this Philips machine is 30,000
gauss, Which means it’s about 30,000
times stronger than the earth’s natural
magnetic field.’’
Re earch 工s in many areas of basic
nd clinical sciences, Particularly neuro-
SCiences and cardiac imagmg, are tum-
mg tO high-field MRI scans because of
the greater resolution and detail they
PrOVide’nOteS Kim・ “This is a maJOr
trend for scientists; he says.
Going even further, the center
Of ers researchers the opportunlty tO
control their own MRI scans and to
PrOgram the scamer by providing宜ee
trainmg. Tb start, eVeryOne muSt take
Sa知y trainmg・ αThat,s simply because
We are dealing with a high-field magnet,
and we want to make sure nothing goes
WrOng, S ys Kim・
Some users will simply want to
monitor their scans, nOteS Kim, emPIoy-
mg the center’s technicians. However,
those who want to operate the scanner
Can o so under the supervision of the
C nter’s technicians after undergomg
trainmg. If researchers go through addi-
tional traimng, they can operate the
MRI scann r on their own.
At th  highest level of trainmg,
res archers can leam how to program the
MRI scanne ・ “This is a great opportunity
or research・ Nomally’yOu are limited to
Only the set of programs or techniques
that the vendo  thinks would be relevant
to you;’says K m. “But we have a research
agreement with Philips, SO We are a皿owed
to reprog am血  scamer. That, Of course,
is the meanmg Of a true research scamer.
We can start to develop novel techniques
and modalities:’
The powerfu1 3-teSla magnet is
also well suited for what is known as
functional MRI (fMRI). This allows
researchers to capture the action-Or
function-Of an organ by tracking
Changes in the level of oxygen in the
blood. Kim explains how an fMRI of the
br in works as an example of this tech-
mque. When the brain is stimulated,
neurons respond and consume energy,
he s ys, uSmg OXygen from the blood-
stream as fllel. The bloodstream trans-
POrtS OXygen Via a molecule called
hem globin・ A hemoglobin molecule
With oxygen still attached is called oxy-
hemoglob ; after the oxygen has been
tra sferred o the cell it,s called deoxyhe-
mog obin・ These two hemoglobin types
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In the control room, Kim reviews plans for the center. Behind him, a flat-
panel screen displaying an image of a brain is one example of the high-tech 
equipment used in this facility. 
possess different magnetic properties. 
"When the brain is stimulated the neu-
rons become more active and need more 
oxygen. You wil l see only in the area 
where the neurons are more active an 
increase in MRI signals," says Kim. "So 
you do a lot of computational statistics, 
and you get many nice images on screen." 
Neuroscientists pioneered fMRI in 
the early 1990s, says Kim, but other 
researchers are devising ways to 
employ this technique. Yet another 
recently developed modality using 
M R I , called Diffusion Tensor Imaging 
(DTI) , allows researchers to see con-
nections between neurons in the brain. 
"So now you can study brain connec-
tivity using M R I , which is actually 
quite amazing," says Kim. 
To support investigators' work, the 
center includes a mock M R I scanner for 
training subjects and helping them 
become familiar with the process before 
undergoing the actual MRI . "The 
process can be kind of intimidating," 
says Kim. "You're not supposed to move. 
Plus the machine is very loud. So this 
gives researchers a chance to get their 
subjects used to it before spending all 
kinds of money on the actual MRI." 
A preparation room provides space 
for anesthetizing and other prep work. 
In an equipment room, a waveguide 
tube connects to the adjoining room 
with the MRI scanner, allowing for 
video stimulation of subjects, often a 
critical part of fMRI research. (The MRI 
scanner would disrupt the video equip-
ment operation i f it were in the same 
room, notes Kim.) Once they've col-
lected their data, researchers can analyze 
it in the center's computer room. 
Eventually, the center would like to pro-
vide an EKG connection to the scanner 
for cardiology research, adds Kim. 
Kim hopes investigators wi l l come 
in with their questions and work collab-
oratively with the center toward solu-
tions. He says one of his most prominent 
research projects is to develop paradigms 
for longitudinal studies, which use serial 
MRI scans to follow how a disease devel-
ops. "This is a major new line of 
research," says Kim. "Eor the most part 
investigators have been using one-time 
scans of subjects to develop their scien-
tific hypotheses and interpretations. 
Investigators wi l l take other MRIs at cer-
tain points in the subject's life, but the 
scans are often years apart." 
Kim believes a better conceptual 
framework exists for studying certain 
diseases. "For example, i f you are inter-
ested in Alzheimer's, it's clear that 
there's not a single time point that is 
most relevant, but rather what is rele-
vant is to follow with multiple scans 
how this phenomenon develops 
throughout many months and, in some 
cases, years. The disease itself is a collec-
tion of this long-time period of progres-
sion or degeneration that actually builds 
up or makes this case," says Kim. "The 
longitudinal studies or multiple scans of 
the same subject is something done in a 
very systematic way, in my opinion, not 
only in terms of anatomical changes but 
in terms of functional changes and con-
nectivity changes." 
He also sees potential for longitudi-
nal studies in the area of autism. "We 
could follow the development of the 
same autistic child starting very early on 
and follow up for months and years to 
see how his functional properties 
develop. How do the neurons develop 
their connections, for example? What is 
different in the subject?" 
The possibilities, says Kim, are end-
less. "This is an amazing machine," he 
says. " I consider it to be one o f the more 
complicated and fascinating medical 
devices around. There's a good reason 
why the Nobel committee decided to 
award the 2003 prize in medicine for 
major discoveries in M R I . Who knows 
what we'll discover? That's what makes 
it very exciting." • 
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New Appointments 
E D W A R D F E I N B E R G 
Chair of Ophthalmology 
Edward Eeinberg, M D , was recently 
appointed chairman of the Department 
of Ophthalmology at Boston University 
School of Medicine (BUSM) and chief 
of the Division of Ophthalmology at 
Boston Medical Center (BMC). He 
served as acting chairman and chief 
since July 2002. 
Feinberg, who specializes in dis-
eases and surgery of the retina, has also 
recently served as associate director of 
Resident Education for the Department 
of Ophthalmology at BUSM and clini-
cal services director for Ophthalmology 
at BMC. 
After receiving his medical degree 
from Mount Sinai School of Medicine 
in 1971, Eeinberg completed an intern-
ship in internal medicine followed by a 
residency in ophthalmology and a fel-
lowship in retina disease and surgery at 
the University of Michigan. For 19 years 
he combined private practice with service 
as a faculty member at the University of 
Tennessee College of Medicine Clinical 
Education Center, Chattanooga, where 
he was associate professor of ophthal-
mology. He also held the positions of 
director of the Retina Service, residency 
program head, and department chairman. 
After moving to Boston in 1997, 
Eeinberg received his master's degree 
from the Harvard University School of 
Public Health in 1998, with a concentra-
tion in health care policy and manage-
ment. He also served on staff at the 
Massachusetts Eye and Ear Infirmary 
and came to Boston University Medical 
Center (BUMC) in 1999. 
Feinberg is an associate examiner for 
the American Board of Ophthalmology 
and a member of several professional 
organizations, including the American 
Academy of Ophthalmology and the 
New England Ophthalmological Society. 
He has published numerous journal 
articles and received resident teaching 
awards at BUMC, the Massachusetts Eye 
and Ear Infirmary, and the University of 
Tennessee. He is also the recipient of the 
American Diabetes Association Physician's 
Award of Excellence and the Lions Club 
Humanitarian Service Award. 
A L E X A N D E R N O R B A S H 
Chair of Radiology 
Alexander Norbash, MD, was appointed 
chairman of the Department of Radiology 
at BUSM and chief of Radiology at BMC. 
His research interests have con-
centrated on neurointerventional tool 
development for the treatment of vas-
cular disorders of the brain and spinal 
cord, specifically focusing on aneurysms, 
stroke, and the treatment of athero-
sclerotic disorders. 
Previously Norbash was director 
of Diagnostic and Interventional 
Neuroradiology at Boston's Brigham 
and Women's Hospital and was an asso-
ciate professor at Harvard University 
School of Medicine. He is the founding 
director of the Interventional Neuro-
radiology and Endovascular Neuro-
surgery Divisions of the Brigham and 
Women's Hospital and was formerly 
an interventional neuroradiologist at 
Massachusetts General Hospital (MCH) . 
Prior to his appointments at M C H , 
Norbash was an interventional and 
diagnostic neuroradiologist, director of 
Head and Neck Imaging, and director of 
Neuro-Magnetic Resonance Therapy at 
Stanford University Hospital from 1994 
to 1998. 
Norbash received his medical degree 
from the University of Missouri-Kansas 
City. He performed his radiology resi-
dency at Saint Francis Medical Center and 
the University of Pittsburgh. At Stanford 
University Hospital, Norbash served as a 
fellow in diagnostic neuroradiology and 
interventional neuroradiology. 
He has lectured nationally and inter-
nationally, authored hundreds of presen-
tations and articles, and has published 
extensively. He belongs to many profes-
sional organizations, including Alpha 
Omega Alpha, the Radiological Society of 
North America, and the American Stroke 
Association. Additionally, Norbash has 
developed clinical products that are cur-
rently used to treat vascular disorders of 
the head, neck, and spine. 
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S T E V E N W I L L I A M S 
Chair ad interim, Department of 
Rehabilitation Medicine 
Steven Williams, MD, has been 
appointed chairman ad interim of the 
Department of Rehabilitation Medicine 
at BUSM and chief ad interim of 
Rehabilitation Services at BMC. He had 
been acting chairman and chief prior to 
this appointment. 
Williams received his medical 
degree from the Eastern Virginia 
Medical School. He performed his resi-
dency at Boston University School of 
Medicine and the Rusk Institute for 
Rehabilitation Medicine at New York 
University. He is a member of numer-
ous professional organizations, includ-
ing the American Academy of Physical 
Medicine & Rehabilitation, the 
American Spinal Injury Association, 
and the American Paraplegia Society. 
He also has authored many publications 
and abstracts and delivered numerous 
lectures and other presentations. 
In 1997, Williams received the 
American Medical Association/Claxo-
Wellcome National Resident Award for 
both outstanding community service 
and leadership. He is founder of Coats 
for Kids and has made several medical 
missions to Kenya as part of Operation 
Smile International. He also is the 
founder of Friends of the New England 
Regional Spinal Cord Injury 
Association. 
Boston University School of Medicine's 
(BUSM) Department of Anatomy and 
Neurobiology, led by Mark Moss, PhD, 
professor of anatomy and neurobiology, 
has been selected as a partner in the 
Carnegie Initiative on the Doctorate, a 
multiyear research and action project 
aimed at improving doctoral education 
in American universities. The depart-
ment is one of 51 partner sites selected 
throughout the country to analyze their 
doctoral programs and create design 
experiments with the aim of improving 
doctoral education. Of those 51 sites, 
nine are focusing on neuroscience. 
Karen Freund, MD, 
MPH, professor of 
medicine at BUSM, 
and chief of the 
Women's Health 
Unit and director 
of the Center of 
Excellence in 
Women's Health at Boston Medical 
Center (BMC), is one of 45 senior 
women faculty from medical and dental 
schools to have been selected as 
2003-2004 fellows by the Hedwig 
van Ameringen Executive Leadership in 
Academic Medicine (FLAM) Program 
for Women. FLAM is the only in-depth 
national program that prepares senior 
women faculty for leadership positions 
at academic health centers. 
Haralambos Gavras, MD, professor of 
medicine at BUSM and chief of the 
Hypertension and Atherosclerosis 
Section at BMC, won the International 
Society of Hypertension's 2004 Eranz 
Volhard Award for his research on the 
renin-angiotensin system, as well as 
clinical and experimental hypertension. 
Given every two years, the award is the 
highest honor bestowed by the society. 
Leonard Gottlieb, 
MD, MPH, chairman 
emeritus of the 
Department of 
Pathology and 
Laboratory Medicine 
at BUSM, was 
recently honored at 
a ceremony dedicating the Leonard S. 
Gottlieb Conference Room at Boston 
University Medical Center (BUMC). 
Gottlieb, who also was the former direc-
tor of the Mallory Institute of Pathology 
at BMC, served BUSM and BMC and its 
predecessors for 50 years. 
Maureen Kavanah, MD, associate pro-
fessor of surgery at BUSM and surgical 
oncologist at BMC, has been appointed 
to the Central Institutional Review 
Board of the National Cancer Institute 
for three years. 
Joseph Korn, MD, 
AJan S. Cohen 
Professor of 
Medicine in 
Rheumatology and 
director of the 
Arthritis Center at 
BUSM, was recently 
honored at the inaugural Gala of the 
Scleroderma Foundation for his 
achievements and his commitment to 
scleroderma research. Korn, chief of 
Rheumatology at BMC, received a spe-
cial copy of the Congressional Record of 
October 28, 2003, in which U.S. Rep. 
Stephen Lynch summarized Korn's ded-
ication and contributions to sclero-
derma research and patients afflicted 
with the disease. 
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Ewa Kuligowska, 
MD, professor 
of radiology at 
BUSM and chief. 
Ultrasound Section, 
Division of 
Radiology at BMC, 
has been elected 
president of the American Association 
for Women Radiologists for 2004. The 
association, founded in 1981, currently 
has more than 1,500 members, as well as 
additional international chapters. 
Joseph Loscalzo, 
MD, PhD, Wade 
Professor, chairman 
of the Department 
of Medicine at 
BUSM, and director 
of the Whitaker 
Cardiovascular 
Institute, was named editor of the scien-
tific journal Circulation: Journal of the 
American Heart Association. His 
appointment becomes effective July 
2004 when the current editor's term 
ends. Loscalzo has served on the edito-
rial boards of several of the association's 
journals, including Hypertension, 
Circulation Research, Circulation, and 
Atherosclerosis, Thrombosis, and Vascular 
Biology. He also serves as physician-in-
chief of the Division of Medicine and 
president of the Evans Medical 
Foundation for BMC. 
NitroMed, a pharmaceutical company 
developing nitric oxide enhancing medi-
cines, and BUSM recently formed a 
multi-year research collaboration to 
support basic research into the clinical 
and pharmacologic roles of nitric oxide. 
To support this research NitroMed, 
which is headquartered in Bedford, 
Mass., opened a second research facility 
in BU's BioSquare. Joseph Loscalzo, 
MD, PhD, Wade Professor, chairman of 
the Department of Medicine at BUSM, 
and director of the Whitaker 
Cardiovascular Institute, is NitroMed's 
scientific founder. 
Janet Osterman, MD, assistant profes-
sor of psychiatry at BUSM and psychia-
trist at BMC, has been named 
distinguished fellow by the American 
Psychiatric Association. Osterman, who 
specializes in post-traumatic stress dis-
order, received the honor in recognition 
of her significant contributions to 
psychiatry. 
Stephen Pelton, 
MD, professor 
of pediatrics at 
BUSM, chief of 
Pediatric Infectious 
Diseases at BMC, 
and professor of 
epidemiology at 
BU's School of Public Health, has been 
elected president of the Massachusetts 
Infectious Diseases Society. His two-year 
term began July 1, 2003. 
Harilaos Sakellarides, MD, assistant 
clinical professor of orthopedic surgery 
at BUSM, has been named a fellow of 
the Royal College of Physicians and 
Surgeons and recently became a member 
of the American Academy of Minimally 
Invasive Spinal Medicine and Surgery. 
Richard Shemin, MD, professor and 
chairman of Cardiothoracic Surgery at 
BUSM, and chief of Cardiothoracic 
Surgery and vice chairman of the 
Division of Surgery at BMC, has been 
appointed president-elect of the 
Northeast Affiliate, Greater Boston 
Division of the American Heart 
Association. Shemin's term wi l l run 
through July 2005. 
Elizabeth Simons, PhD, professor of 
biochemistry at BUSM and assistant 
director for basic sciences in the Office 
of Medical Education, received the Cano 
Dunn Award for professional achieve-
ment in science and engineering this 
spring from her alma mater Cooper 
Union in New York City. Simons is only 
the second woman to receive the award, 
which was instituted in 1955. 
M/BP \ > •'^ d Tauber, MD, 
' ^ ^ ^ % v professor of medi-
cine, pathology, and 
laboratory medicine 
at BUSM, and pro-
fessor of philosophy 
and director of the 
Center for 
Philosophy and History of Science at 
BU, has been named the first Zoltan 
Kohn Professor of Medicine. Tauber 
joined the BU faculty in 1982, when he 
became chief of the Hematology and 
Oncology Service at the former Boston 
City Hospital. He led that section for 13 
years while also making important sci-
entific contributions to the field of 
inflammation and the cell biology of 
leukocytes, the white blood cells instru-
mental in fighting infection. 
At the same time, Tauber cultivated his 
interests in the history of immunology, 
bioethics, and the philosophy of science. 
In 1993, he accepted a formal appoint-
ment in the Department of Philosophy 
at BU's College of Arts and Sciences, 
where he currently instructs graduate 
and undergraduate students. He has 
published extensively on 19th- and 
20th-century biomedicine and biomed-
ical ethics, including Confessions of a 
Medicine Man, An Essay in Popular 
Philosophy (MIT, 1999). Tauber also 
teaches ethics at BUSM, is a member of 
the Hematology-Oncology Section at 
BMC, and is a member of BUSM's 
Board of Visitors. 
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Grants and Major Contributions 
Trust to Benefit Neurosciences 
Jack Spivack, a Washington, D.C. resi-
dent and long-time member of Boston 
University School of Medicine's (BUSM) 
Board of Visitors, established an irrevo-
cable trust that upon maturation wi l l 
donate $7 mil l ion to BUSM to name 
the Spivack Center for Behavioral 
Neurosciences. Behavioral Neuroscience 
represents a major growth area in bio-
medical sciences, and Spivack's generous 
gift wil l position BUSM as one of the 
world's premier centers. Spivack became 
involved with BUSM when a close rela-
tive and first-year medical student expe-
rienced difficulty in adjusting to the new 
and challenging experience. Spivack 
appreciated the sensitive treatment his 
relative received and became a donor, 
supporting BUSM steadily ever since. 
Annuity Created for Infectious 
Disease Research 
Henry Wolfe, M D '45, and his wife, 
Crace, established the Henry and Crace 
Wolfe Scholarship Fund. Upon matura-
tion, the $100,000 annuity wi l l benefit 
students in the M D program at the 
School of Medicine or in the MD/PhD 
program in the Division of Graduate 
Medical Sciences. During his career 
Wolfe focused on infectious diseases, so 
preference wil l be given to students 
interested in this area of study. Wolfe 
hopes the scholarship wi l l stimulate 
research in infectious diseases. 
Professorship Honors Two 
Nearly $1.3 mill ion has been committed 
to establish the M . Stuart Strong and 
Charles W. Vaughan Professorship in 
Otolaryngology. M . Stuart Strong, M D , 
a former chairman of BUSM's 
Department of Otolaryngology, and 
Charles Vaughan, M D , worked together 
in the department for more than two 
decades, turning it into one of the best 
in the world. They were the first to use 
laser in otolaryngology surgery, for 
example, transforming the field and 
greatly improving the lives of patients. 
Numerous former residents and col-
leagues have contributed to the 
Department's initiative. 
Gift Establishes New Lab 
The Fannie E. Rippel Foundation 
invested $320,000 to create the 
Molecular Diagnostic Research 
Laboratory in BUSM's Department of 
Surgery. This project, directed by Peter 
Thomas, PhD, professor of surgery, 
partners surgeons and laboratory scien-
tists in translational research that wi l l 
benefit cancer patients as their probabil-
ity for disease recurrence is identified, 
helping to individualize treatment. 
Grant Aids Biomedical Engineering 
Initiative 
BUSM received $1,025,000 from the 
Whitaker Foundation in support of the 
Whitaker Leadership Development 
Program in Biomedical Engineering, a 
multiyear interdisciplinary project con-
ducted in partnership with BU's College 
of Engineering. Biomedical engineering 
uses cutting-edge techniques to under-
stand how the body's processes and 
structure, from the level of individual 
genes to whole organs, relate to disease. 
Donation to Benefit Alzheimer's 
Center 
The Fidelity Foundation donated 
$150,000 to the BUSM Alzheimer's 
Disease Research Center. The center, 
which conducts clinical research and 
receives approximately 3,000 visits 
annually, is also supported by more than 
$ 11 mil l ion in funding from the 
National Institutes of Health and the 
Alzheimer's Association. 
Grant Supports Study of Elderly 
Health Care 
Sharon Levine, M D , associate professor 
of medicine at BUSM and geriatrician at 
Boston Medical Center (BMC), received 
a grant for nearly $2 mil l ion from the 
Donald W. Reynolds Foundation. The 
grant is one of ten awarded by the foun-
dation's Aging and Quality of Life pro-
gram, an initiative designed to improve 
the quality of health care for elders 
throughout the United States by training 
physicians to address elders' special 
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health-care needs. The grant funding 
supports the establishment of the 
Boston University Medical Center 
Comprehensive Geriatric Education 
Project. This four-year geriatrics educa-
tion initiative at BUSM, BMC, and the 
affiliated Boston Neighborhood Health 
Center Network wi l l strengthen the 
training of medical students, residents, 
faculty, and practicing physicians in 
geriatrics. 
Two Researchers Receive Grants 
Philip Morris provided Wandi Li , PhD, 
associate research professor, with con-
tinuation funding of $368,600 for his 
study "Mechanisms of Perturbation of 
Pulmonary Lysyl Oxidase by Cigarette 
Smoke" and Victoria Herrera, M D , 
associate professor of medicine, with 
$399,358 for her study "Integrated 
Molecular Analysis of Nicotine-
Hypertension-Hyperlipidimia 
Interaction in CHD." 
BUSM to Lead New Consortium 
Peter Merkel, M D , M PH, assistant pro-
fessor of medicine at BUSM, wi l l be the 
director and principal investigator of 
a new multicenter Vasculitis Clinical 
Research Consortium (VCRC). Funded 
by a five-year, $6.25 mill ion grant from 
the National Institutes of Health, the 
VCRC wi l l focus on investigations in the 
inflammatory vasculitides, rare diseases 
linked to inflammation of the blood 
vessels. BUSM wi l l serve as the lead 
medical center in the consortium; the 
other centers include the Cleveland 
Clinic, Johns Hopkins University, and 
the Mayo Clinic, as well as centers in 
Canada, France, and Germany. 
BUSM Affiliate Wins N I H Grant 
The Roger Williams Medical Center 
in Providence, R.I., a clinical affiliate 
of BUSM, was awarded a five-year, 
$ 13 mill ion grant from the National 
Institutes of Health (NIH) to further its 
studies into adult stem cells. The grant 
comes from the NlH's Center of 
Biomedical Research Excellence pro-
gram, which aims to help research cen-
ters nurture junior scientists, build new 
labs, and buy new equipment. Peter 
Quesenberry, M D , chairman of Roger 
Williams' Department of Research and 
head of the Center for Stem Cell 
Biology, is the principal investigator for 
the grant. 
Prostate Cancer Research Funded 
Douglas Ealler, M D , PhD, professor of 
medicine at BUSM and vice chairman 
of the Section of Hematology/Oncology 
at BMC, has received a $600,000 grant 
from the Prostate Cancer Research 
Program of the U.S. Department of 
Defense's U.S. Army Medical Research 
and Materiel Command. Faller's 
research project is titled "Sensitization 
of Prostate Tumors to Retinoids by 
Short-Chain Fatty Acids." 
Researcher Receives $2 Million Grant 
The National Heart, Lung, and Blood 
Institute has provided Noyan Gokce, 
M D , assistant professor of medicine at 
BUSM and staff cardiologist at BMC, 
with a five-year, $2 mil l ion grant to 
study the therapeutic effects of different 
modalities of weight loss on vascular 
function and adipocyte metabolism. 
N I H Grant Provides Ongoing 
Support 
Bertram Payne, PhD, professor of 
anatomy and neurobiology at BUSM, 
has received a $2.7 mil l ion grant from 
the National Institutes of Neurological 
Diseases and Stroke, a division of the 
National Institutes of Health ( N I H ) . 
The five-year award w i l l help Payne and 
his researchers study "Rehabilitation of 
Neural Spatial Neglect." The new funds 
add to the more than $3 mil l ion of sup-
port that Payne has received from the 
N I H for ongoing research. 
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Alumni Awards 
The Boston University School of Medicine (BUSM) Alumni Association annually confers 
two types of awards on alumni. Its Distinguished Alumnus/Alumna Award recognizes out-
standing clinical, teaching, and research careers, and its Humanitarian Award acknowledges 
graduates who have made a significant contribution to the betterment of society. 
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Philip Barie, MD 77 
Philip Barie, M D '77, is professor of 
surgery aud public health at the Joau 
aud Sauford I . Weill Medical College of 
Coruell Uuiversity; chief of the Divisiou 
of Critical Care aud Trauma aud chief 
of the Prestou A. Wade Surgical Service 
at New York-Presbyteriau Hospital; aud 
director of the Auue aud Max Coheu 
Surgical luteusive Care Uuit of New 
York-Presbyteriau Hospital. 
A uatioually recoguized expert iu 
surgical critical care aud trauma, Barie's 
research focuses ou the pathophysiology 
of acute respiratory failure, systemic 
respouses iu ischemia-reperfusiou 
iujury, the epidemiology of critical sur-
gical illuess, aud the epidemiology of 
multiple orgau dysfuuctiou syudrome. 
He has published more thau 400 articles, 
mauuscripts, aud abstracts, aud his book 
Surgical Intensive Care has beeu recog-
uized as oue of the best health-scieuce 
books aud received the Best New Book: 
Medical Scieuce award from the 
A W A R D S 
Associatiou of Americau Publishers 
Professioual aud Scholarly Publishiug 
Divisiou. 
Barie has beeu listed iu Who's Who 
in Medicine and Health Care, Who's Who 
in the World, and Who's Who in America. 
He is presideut of the Easteru 
Association for the Surgery of Trauma 
aud presideut of the Surgical Infection 
Society, aud he has served as presideut 
of the New York State Society of 
Surgeons. He is a fellow of the Americau 
College of Critical Care Medicine aud 
a fellow of the Americau College of 
Surgeons. Additionally, he is editor of 
Surgical Infections and is ou the editorial 
board of the Journal of Trauma and 
Critical Care Medicine. 
Iu 2003, he received his MBA 
degree from Auburn Uuiversity Lowder 
School of Business. 
David Faxon, MD 71 
David Faxon, M D '71, is professor of 
medicine aud chief of the Section of 
Cardiology at the Uuiversity of Chicago. 
A world-reuowued specialist iu iuter-
veutioual cardiology, Faxon helped pio-
neer the development of angioplasty. 
With more thau 370 publications aud 
four books to his credit, he is best 
known for his research ou the mecha-
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H U M A N I T A R I A N A W A R D 
Carolann Najarian, MD '80 
i"f nit;"" 
nisms and prevention of restenosis 
after angioplasty. 
Faxon was a member of the BUSM 
faculty from 1976 to 1993, serving as 
director of the Cardiac Catheterization 
Laboratory and associate director of 
cardiology at University Hospital (now 
Boston Medical Center). In 1993, he 
joined the faculty of the University of 
Southern California (USC) Medical 
School as professor of medicine and 
chief of the Division of Cardiology at 
the Los Angeles County+USC Medical 
Center and USC University Hospital. 
His current research includes the 
role of collagen metabolism iu vascular 
remodeling, cytokines iu restenosis, 
the role of local drug delivery, aud 
intravascular radiation iu the prevention 
of restenosis, as well as participation iu a 
number of multicenter clinical trials iu 
the area of interventional cardiology aud 
acute coronary syndromes. In addition, 
he patented a catheter for delivery of 
therapeutic aud diagnostic agents to the 
tissue surrounding a body passageway. 
He is regularly included ou 
lists of the best cardiologists iu the 
United States. He is presideut of the 
Americau Heart Associatiou aud a past 
presideut of the Society for Cardiac 
Angiography aud Interventions. He also 
serves ou the editorial boards of a 
number of journals, including 
Circulation, the American Journal of 
Cardiology, and the Journal of the 
American College of Cardiology. 
Carolann Najarian, M D '80, is presideut 
of the Armenian Health Alliance, a non-
profit organization she helped found iu 
response to the 1988 earthquake that 
devastated northern Armenia. 
Najarian has made more thau 50 
trips to the Republic of Armenia aud 
to the Nagoruo Karabakh Republic to 
assess the medical needs iu these regions 
aud to deliver millions of dollars worth 
of assistance to villages, maternity aud 
pediatric hospitals, aud orphans aud 
refugees. In 1994, Najarian founded the 
Primary Care Center of Cyumri, the city 
most devastated by the earthquake. With 
the financial support of the Armenian 
Health Alliance, primary care doctors 
aud nurses provide care aud medicine 
free of charge to more thau 400 patients 
a mouth, most of whom are indigent 
aud elderly. The Alliance also supports 
the Huys Orphanage iu Cyumri. 
In 1995, Najarian founded the 
Arpeu Center for Expectant Mothers iu 
the city of Stepanakert, the capital of 
Nagoruo Karabakh. The center provides 
monthly assistance of food, vitamins, 
clothing, aud other basic necessities to 
pregnant women. It also distributes 
information ou pregnancy, good health, 
aud diet. Approximately 7,000 women 
have beeu served by the Arpeu Center, 
aud nearly 700 women come to the cen-
ter each mouth. Najarian spends about 
three mouths each year iu Armenia aud 
Karabakh supervising these projects, 
teaching, aud consulting wi th patients. 
She also has written the book A Call 
From Home; Armenia and Karabagh, My 
Journal, which documents her experi-
ences during nearly a decade of human-
itarian work iu the region. 
Najarian is a diplomate of the 
Americau Board of Internal Medicine 
aud has beeu a practicing internist i u 
the Cambridge aud Watertowu, Mass. 
area. She is assistant medical director 
of Middlesex County Hospital, a 
member of the medical staff of St. 
Elizabeth's Medical Center aud of 
Mount Auburn Hospital, aud an 
instructor iu clinical medicine at 
Harvard Medical School. After years iu 
private practice, Najarian left active 
medical practice to volunteer full time 
as presideut of the Armenian Health 
Alliance. The recipient of numerous 
awards, she was presented wi th the Ellis 
Island Medal of Honor iu 1999. 
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Norman Levinsky, MD, of Newton, 
Mass., on March 8, 2004, at the age of 
74. Dr. Levinsky was known for his 
intellect, his outstanding teaching abili-
ties, and his rigorous standard of med-
ical ethics. 
He was a leader at Boston University 
Medical Center (BUMC), spending more 
than 40 years here. He served as chief 
of Renal Section in the Department of 
Medicine at Boston University School 
of Medicine (BUSM) from 1967 to 1968 
and then 1971 to 1987, and as chairman 
of the Department of Medicine from 
1972 to 1997, making him one of the 
longest-serving chairs of an academic 
medical department in the nation. In 
1997, Dr. Levinsky stepped down to 
become associate provost at Boston 
University Medical Campus, and was 
recently named acting provost of the 
Medical Campus. 
Dr. Levinsky graduated from 
Harvard Medical School and completed 
his residency at Beth Israel Hospital in 
Boston. After his residency, he was a 
clinical associate at the National Heart 
Institute and then became a fellow in 
medicine at BUMC. 
"He was a brilliant administrator 
who led Boston University's and Boston 
Medical Center's Department of Medicine 
and the Evans Medical Eoundation for 
a remarkable 25 years," says Aram 
Chobanian, MD, president ad interim, 
Boston University, and a colleague of 
Dr. Levinsky for more than 40 years. " I 
always gave Norman the toughest prob-
lems to deal with, knowing full well that 
he would accomplish the task in his 
typically thoughtful, meticulous, and 
creative manner." 
During his career Dr. Levinsky 
authored more than 150 publications on 
subjects ranging from kidney function 
and renal disease to health policy ethics 
and education. He also was a member of 
many renowned academic societies, 
including the Institute of Medicine of the 
National Academy of Sciences, the 
American Society for Clinical 
Investigation, the Association of 
American Physicians, and the Association 
of Professors of Medicine. He chaired 
two national committees of the Institute 
of Medicine, including the Committee to 
Study End-Stage Renal Disease Program 
and the Committee on Xenograft 
Transplantation: Science, Ethics, and 
Public Policy. Each report influenced fed-
eral regulations in their respective areas. 
Until recently, he also directed a kidney 
research laboratory for which he received 
30 continuous years of funding from the 
National Institutes of Health. 
"Dr. Levinsky built the department 
into one of the best in the country with 
the recruitment of many outstanding 
academicians," says BUSM Acting Dean 
John McCahan. 
Respected as an outstanding 
teacher as well. Dr. Levinsky's renal 
rounds were legendary. His teaching 
earned him numerous accolades and 
awards, including the prestigious 
Distinguished Teacher Award for the 
American College of Physicians, as well 
as recognition as an Outstanding 
Faculty Member by BUSM students and 
Teacher of the Year by the medical resi-
dents. Additionally, every year he met 
with each House Officer on an individ-
ual basis to provide advice and counsel. 
" I enjoy teaching enormously," 
Dr. Levinsky said in a recent interview. 
" I love interacting with the students, the 
trainees, and the residents. They bring 
fresh, new ideas and have interesting 
viewpoints on every issue. I have 
reached the stage where the children of 
some of my first students are here at the 
School or in the residency program. It is 
gratifying to see that." 
As a champion of patients. 
Dr. Levinsky wrote articles on ethics 
that were widely read by policy makers 
and students of medicine. He stressed 
that the needs of patients should come 
before their financial interests and that 
the elderly deserve equal care, for exam-
ple. But he went beyond writ ing about 
ethics and took time to talk with his 
patients, carefully explaining their med-
ical conditions and treatment options. 
"Norman was one of the leading 
architects of our Medical Campus as it 
exists today, and his death represents a 
serious loss for all of us," adds Chobanian. 
"1 wi l l truly miss his many, many years 
of friendship and his wise counsel." 
He is survived by his wife, Elena; 
two sons, Harold and Andy; daughter 
and son-in-law, Nancy and Howard 
Safran; his mother and stepfather, 
Gertrude and Louis Feldman; a sister, 
Ellen Sussman; and three grandchildren. 
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Leonard Cibley, MD, of Newton, Mass., 
on August 26, 2003, at the age of 83. 
An obstetrician-gynecologist. Dr. Cibley 
delivered thousands of babies during his 
four-decade career. 
Graduating from Boston University 
School of Medicine in 1952, he later 
joined its staff in 1965 as a clinical assis-
tant, eventually becoming a clinical pro-
fessor of obstetrics/gynecology. Dr. Cibley 
practiced for many years in Waltham 
and Brookline and was on staff at the 
Deaconess-Waltham Hospital. He served 
as chief of the Dysplasia and Colposcopy 
Clinic at Boston City Hospital, now 
Boston Medical Center. He also lectured 
at conferences at Harvard, bringing stu-
dents and colleagues up to date on the 
latest technology in the field. Making his 
own contribution to technology, he 
designed a surgical tool used to perform 
biopsies. 
Dr. Cibley began his career as an 
entertainer and used this background 
to write and direct a movie on family-
centered childbirth called A Labor of 
Love. He also served in the U.S. Navy 
during World War I I as a pharmacist 
mate first class. 
He is survived by his wife, Shirley; 
two sons, Jerold of Foxborough, Mass., 
and Laurence of Texas; a sister, Doris 
Ochs of Waltham, Mass.; and four 
grandchildren. 
Benjamin Kamlner, MD, of Woods 
Hole, Mass., on December 13, 2003, at 
the age of 79. Chairman of the BUSM 
Department of Physiology from 1970 to 
2000, Dr. Kaminer wi l l perhaps best be 
remembered by the more than 5,000 
medical, dental, and graduate students 
who were enthralled by his teaching skills. 
An inspiring educator with a deep 
understanding of physiology and medi-
cine. Dr. Kaminer believed students 
should observe phenomena whenever 
possible instead of simply reading about 
it. He would present hemodynamic prin-
ciples with reservoirs and tubes, for 
example, or demonstrate respiration by 
balancing precariously on a stage table to 
expand an isolated lung in a bell jar. He 
also advocated hands-on experiments. 
His efforts won him numerous awards, 
including the Stanley L. Robbins Award 
for Excellence in Teaching and the 1998 
University Scholar/Teacher of the Year 
Award. Dr. Kaminer also lectured on 
anatomy at Harvard Medical School. 
Having spent most of his youth 
in South Africa, Dr. Kaminer received 
his medical degree in 1946 from 
the University of Witwatersrand in 
Johannesburg. He then earned his 
degree in Child Health from the Royal 
College of Physicians 8c Surgeons in 
England. He came to the United States 
in 1959 when he received the Rockefeller 
Foundation Fellowship and began work 
at the Marine Biology Laboratory 
(MBL) in Woods Hole, Mass., where 
he remained for ten years. 
Dr. Kaminer had a wide range 
of research interests as well. While at 
BUSM his research focused mainly on 
the calcium regulatory mechanism in 
striated and smooth muscle, although 
through his long-standing endeavors 
at the Woods Hole MBL each summer 
he also studied a range of calcium-
regulated processes in other animal 
model systems. His work was published 
in some of the most prestigious interna-
tional scientific journals. 
He was a member of the Board of 
Trustees at the MBL from 1976 to 1984, 
S 
\ 
on its executive committee from 1976 
to 1979, and chairman of its instruction 
committee from 1975 to 1980. He was 
a long-standing chairman of the schol-
arship committee of the Society of 
General Physiologists and served on 
the Board of Trustees for the Harvard 
Apparatus Eoundation, the Mountain 
Foundation Fellowship, and the Will iam 
Townsend Porter Eoundation. 
Dr. Kaminer is survived by his wife, 
Freda; son, Brian; and daughter, Lauren, 
all of Woods Hole. 
Theodore Nadelson, MD, of Brookline, 
Mass., on October 20, 2003, at the age of 
73. A professor of psychiatry at BUSM 
and formerly vice chairman for educa-
tion in the Division of Psychiatry, 
Dr. Nadelson was known as an outstand-
ing educator, a wonderful lecturer, and a 
great wit and listener. 
Dr. Nadelson served in the Army 
for several years, and then following his 
service he earned a master's degree at 
the University of California at Berkeley 
and a medical degree from UC-San 
Francisco in 1960. In 1968 he moved to 
Boston and became a resident at Beth 
Israel Hospital. He taught at Harvard 
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and Tufts medical schools and for the 
past seven years at BUSM. In recogni-
tion of his teaching, he was awarded the 
Jacob Schwarz, M D , Outstanding 
Teacher Award by the BUSM class of 
2003 psychiatry residents. 
Dr. Nadelson's expertise was in psy-
chosomatic disorders, consultation-
liaison psychiatry, and, more recently, 
war-related post-traumatic stress disor-
der, tie authored more than 50 profes-
sional papers, including pioneering 
articles on Munchausen syndrome, and 
he served as chief of psychiatry at the VA 
Boston Healthcare System, Jamaica Plain 
campus, until his retirement in 1997. 
He is survived by his wife, Carol; 
son, Robert, of New York City; daughter 
and son-in-law, Jennifer and Michael, 
and granddaughter, Sarah, all of Boston. 
Stanley Robbins, MD, of Cambridge, 
Mass., on Cctober 7, 2003, at the age of 
88. A respected physician and professor. 
Dr. Robbins was perhaps best known as 
the revolutionary author who brought 
the study of pathology to life for medical 
students with his textbooks. By taking a 
conversational tone in his writings. Dr. 
Robbins made the subject more accessi-
ble to students. He also emphasized the 
mechanisms that underlie illnesses, help-
ing students understand why a disease 
happens and what it does to a patient. 
After attending Tufts Medical 
School, at which he delivered the vale-
dictory address. Dr. Robbins trained at 
Boston City Hospital. He taught at BU, 
Harvard, and Tufts medical schools, and 
he took a post at BU's Mallory Institute 
of Pathology, of which he became direc-
tor in 1965. Dr. Robbins also served as 
chairman of the BUSM Department of 
Pathology from 1966 to 1979. It was 
while lecturing on pathology at BUSM 
that he decided to write a textbook, say-
ing the available pathology books were 
too dry. Initially Dr. Robbins couldn't 
find a publisher, but his persistence paid 
off and the first edition. Textbook of 
Patbology, was published in 1957. Today 
more than two million copies have been 
sold, and the book endures as Robbins' 
Patbologic Basis Disease. 
Dr. Robbins also did some notable 
research, helping develop the frog preg-
nancy test, a precursor to the rabbit test 
and at one point the standard test for 
pregnancy worldwide. He did some 
early research into coronary artery 
disease as well. 
He is survived by his children, 
Jonathan of Swampscott, Mass., 
Rebekah (Robbins) of Homestead, Fla., 
and Jeffrey Mark of Swampscott; six 
grandchildren; one great-grandchild; 
and his companion, Joan Wylie. His 
wife, Eleanor, died in 1996. 
Eli Shapiro, MD, of Newton, Mass., on 
November 30, 2003, at the age of 89. A 
family doctor for 65 years. Dr. Shapiro 
was known for the personal care he gave 
his patients, still making house calls 
until eight months before his passing. 
He treated generations of patients from 
the same family and kept in touch with 
many of them throughout all the years. 
While attending a six-year medical 
program at the University of 
Massachusetts and Middlesex College of 
Medicine and Surgery, Dr. Shapiro vol-
unteered at Boston City Hospital dur-
ing the summers. After graduating in 
1937, he passed the State Board 
Examination and soon afterward began 
his private practice. From 1943 to 1946, 
he put his practice on hold and served 
as a captain in the Army Medical Corps 
in Tennessee, Belgium, and Italy. Once 
back from overseas, he reopened his 
private practice. 
Dr. Shapiro was affiliated with 
Boston Medical Center and was a 
BUSM assistant clinical professor in the 
Department of Family Medicine since 
1973. He served as a consultant to the 
BUMC Continuing Education Advisory 
Committee and volunteered his services 
at BUMC's Outpatient Department for 
20 years. He also was awarded the 
Distinguished Physician Award by the 
Evans Medical Service Department of 
Medicine Housestaff. 
He was a life member of the 
Middlesex chapter of the Brandeis 
University Club, and he was an organiz-
ing committee member of the 
Middlesex Healing Arts Foundation. He 
was a diplomate of the American Board 
of Family Practice from 1983 to 2004 
and received its Award of Merit in 1977. 
He also was a member and charter fel-
low of the American Academy of Family 
Physicians. 
He is survived by his wife, Barbara 
Michaelson Gould; six children, Edward 
of Lynn, Mass., Laurence Gould 
of Newton, Mass., Amy Gould of 
Brookline, Mass., Kenneth Gould of 
Newton, Mass., Marilyn of New York 
City, and Robert of Oklahoma; a 
brother, Philip of Hyde Park, Mass.; 
and several grandchildren. 
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Jerome L'Heureux, MD '34, of 
Meriden, Conn., on September 28, 2003, 
at the age of 97. Dr. L'Heureux had a 
private pediatric practice in Meriden 
until his retirement in 1985. 
A lieutenant in the U.S. Navy, he 
served in the Pacific during World War 
I I . After the war, he was assigned as head 
of the Department of Pediatrics at 
Chelsea Naval Hospital in Massachusetts. 
During his 50-year medical career, he 
was also on the staff of the Meriden-
Wallingford Hospital and the Veterans 
Memorial Hospital, where he served in 
different capacities, including as chief of 
Pediatrics. Additionally, he was on the 
staff of the Meriden Health Department 
and served as a school physician for 45 
years in most of the schools in Meriden. 
Dr. L'Heureux was a member 
of the American Medical Association, 
Connecticut Medical Society, New 
Haven County Medical Society, 
Meriden-Wallingford Medical Society, 
New England Pediatric Society, Hezekiah 
Beardsley Pediatric Society, and Franco-
American Medical Society. 
Predeceased by his wife, Irene, he is 
survived by his 7 children, 19 grandchil-
dren, and 25 great-grandchildren. 
Harold Chase, MD '38, of Keene, N .H. , 
on October 1, 2003, at the age of 91. An 
anesthesiologist. Dr. Chase formed the 
first Department of Anesthesia at the 
University of Virginia Medical Center in 
Charlottesville in 1949. 
He was a clinical professor of anes-
thesia at Thomas Jefferson University 
Hospital in Philadelphia from 1955 
unti l he retired in 1980. Open-heart 
surgeries were pioneered at this hospi-
tal, and Dr. Chase took part by provid-
ing the anesthesia. 
He is survived by his wife, Elizabeth 
(Wagner) Chase, two sons, a daughter, a 
sister, seven grandchildren, and six 
great-grandchildren. 
Harold Marcus, MD '39, of Boca Raton, 
Ela., on September 8, 2003, at the age of 
88. Dr. Marcus served as chief of 
Medicine at the International Ladies 
Garment Workers Union Health Center 
in New York City from 1953 to 1996 and 
had a private practice in Brooklyn from 
1949 to 1988. 
A lieutenant colonel in the U.S. 
Army from 1941 to 1946, Dr. Marcus 
received the Bronze Star and was the 
recipient of the General Chiang Kai-
shek Merit Citation. He was a diplomate 
of the National Board of Medical 
Examiners and the American Board of 
Internal Medicine. 
He is survived by his wife, Beatrice, 
two sons, and three grandchildren. 
Eleanor Mendel! Worsley, MD '43-B, of 
Baton Rouge, La., on December 4, 2003, 
at the age of 85. An internist and 
family practitioner. Dr. Worsley was 
Natchitoches Parish's first woman doc-
tor. In practice for 54 years, she was 
revered for her dedication to the poor, 
making charitable house calls to her 
rural patients regardless of the weather 
or the travel conditions. She organized 
the first intensive care unit at the 
Natchitoches Parish Hospital, and she 
helped found the Alzheimer's facility in 
Natchitoches' Heritage Manor, which 
was later named for her. 
Dr. Worsley's first medical office was 
dedicated to her in 1974 as the Bayou 
Folk Museum, and the Louisiana State 
Medical Society honored her in 1993 for 
her continuous 50-year practice. Upon 
her retirement in 1998, Dr. Worsley was 
honored by the Louisiana governor, legis-
lature, and the city of Natchitoches for 
her tireless work and social dedication. 
She was chosen as one of Louisiana's 
Women of the Century in 2000. 
Predeceased by her husband, 
Donald Harlow Worsley, she is survived 
by her daughter, grandson, and brother. 
Walter Cervoni, MD '49, of Guaynabo, 
Puerto Rico, in October 2003, at the age 
of 77. A clinical pathologist. Dr. Cervoni 
worked for the Chief Laboratory Service 
at Doctors Hospital in Santurce and 
Auxilio Mutuo Hospital in Hato Rey. 
He was a consultant for the Veterans 
Administration at San Patricio Hospital 
and taught pathology at the University 
of Puerto Rico in San Juan. 
Dr. Cervoni was a member of the 
United States Public Health Service and 
served in the U.S. Army Medical Corps. 
He also was a member of the Puerto 
Rico Medical Association, American 
College of Physicians, and American 
Society of Tropical Medicine and 
Hygiene. He was a Eellow of the College 
of American Pathologists and the 
American Society of Clinical 
Pathologists, and he was a member and 
state representative for the Puerto Rico-
American Society of Blood Banks. 
He is survived by his wife, Maria 
Ruiz Soler. 
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